Bank of New York Mellon Corp Sells 20,529 Shares of Harvard Bioscience, Inc. (NASDAQ:HBIO)

Bank of New York Mellon Corp reduced its holdings in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) by 8.9% during the fourth quarter, HoldingsChannel reports. The firm owned 209,548 shares of the medical instruments supplier’s stock after selling 20,529 shares during the period. Bank of New York Mellon Corp’s holdings in Harvard Bioscience were worth $442,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of HBIO. JPMorgan Chase & Co. boosted its holdings in Harvard Bioscience by 63.0% in the third quarter. JPMorgan Chase & Co. now owns 29,501 shares of the medical instruments supplier’s stock worth $79,000 after purchasing an additional 11,397 shares during the last quarter. Barclays PLC raised its stake in Harvard Bioscience by 304.4% during the 3rd quarter. Barclays PLC now owns 58,655 shares of the medical instruments supplier’s stock valued at $157,000 after purchasing an additional 44,150 shares during the period. Williams & Novak LLC bought a new stake in Harvard Bioscience in the 4th quarter valued at $209,000. Connor Clark & Lunn Investment Management Ltd. lifted its stake in Harvard Bioscience by 19.7% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 180,006 shares of the medical instruments supplier’s stock worth $484,000 after purchasing an additional 29,607 shares in the last quarter. Finally, State Street Corp boosted its holdings in shares of Harvard Bioscience by 1.1% during the 3rd quarter. State Street Corp now owns 717,387 shares of the medical instruments supplier’s stock valued at $1,930,000 after purchasing an additional 7,763 shares during the last quarter. 80.87% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Benchmark reduced their target price on Harvard Bioscience from $5.50 to $4.50 and set a “speculative buy” rating on the stock in a report on Monday.

Harvard Bioscience Stock Down 1.8 %

Shares of HBIO opened at $0.60 on Friday. The business’s 50 day simple moving average is $1.17 and its 200-day simple moving average is $1.94. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.06 and a quick ratio of 0.91. The stock has a market capitalization of $26.45 million, a price-to-earnings ratio of -1.82 and a beta of 1.46. Harvard Bioscience, Inc. has a 1 year low of $0.56 and a 1 year high of $4.70.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.